# Guoqian Venture Capital

> Guoqian Venture Capital is a VC fund backing Medical and Health Care. See 14 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Haimen, China
- Total investments: 14
- Last investment: Aug 2024
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/guoqianvc/
- Website: http://www.guoqianvc.com/

Guoqian Venture Capital is a VC fund in Haimen focused on Medical and Health Care. Guoqian Venture Capital focuses on the equity investment in the early and middle stage of start-ups in the medical devices, which is an important step to implement the strategic roadmap “Industry + Capital”.

## Contacts

5 contacts available for Guoqian Venture Capital. Shizune tracks 1 team members at Guoqian Venture Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/guoqian-venture-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 8 | 57% |
| Health Care | 6 | 43% |
| Biotechnology | 6 | 43% |
| Manufacturing | 6 | 43% |
| Pharmaceutical | 3 | 21% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 29% |
| Angel | 3 | 21% |
| Series A | 3 | 21% |
| Seed | 2 | 14% |
| Venture - Series Unknown | 2 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chen Hao | Partner | 3 | https://shizune.co/investors/profile/chen-hao-d559 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Jiangsu Junhua | Jiangsu Junhua is an engineering plastics manufacturer specializing in the research and development of high-performance special engineering plastic parts and profiles like PEEK and PI. |  | Venture - Series Unknown | Aug 12, 2024 |  |
| Insaifeiying | Insaifeiying is a manufacturer of innovative medical equipment for minimally invasive surgery. It focuses on the research, development, and manufacturing of intelligent wireless endoscopes. |  | Seed | Mar 18, 2024 |  |
| Yunmao Technology | Yunmao Technology develops precision nano-coating equipment for semiconductor chip manufacturing. |  | Series B | Jun 27, 2023 |  |
| Baikang Bio | Baikang Bio is an in vitro diagnostic and upstream core raw material developer of biological drugs. | $13.4M | Series A | Jan 12, 2023 |  |
| Bioantibody | Bioantibody is a high-tech biotechnology firm specializing in the research and development of antigens, antibodies, and downstream detection reagents for diagnosis and therapy. | $14.8M | Series A | Jan 12, 2023 |  |
| Nenstar Electronic Technology | Leanstar Sensor has developed the core design capabilities of multi-variety and multi-range flexible micro-nano mechanical force sensors. Their products are flexible pressure sensors, flexible piezoelectric sensors, flexible capacitive sensors, flexible thermal sensors, flexible temperature and humidity sensors, and flexible integrated compositemicro-nano sensors. |  | Venture - Series Unknown | Apr 29, 2022 |  |
| BIOSURF | BIOSURF is an innovation-driven healthcare based surface modification technology company. | $15.7M | Series B | Apr 15, 2022 |  |
| Keyto | Keyto specializes in the production of key electrical and mechanical components for microfluid system controls. |  | Series B | Jan 22, 2021 |  |
| MagAssist | Suzhou Xinqing Medical Technology Co., Ltd. was founded in 2017 by Dr. Xu Bozhen, a special expert of the National Youth Thousand People Program and a special professor of Suzhou University. He is a high-tech enterprise with the main goal of developing the world's leading in vitro short-term ventricular assist device (in vitro artificialheart). . The core members of the company's entrepreneurial team are the world's top artificial heart engineering technology experts. With years of experience in overseas artificial heart research and development and productization, the company has developed a domestically produced artificial heart with independent intellectual property rights. | $15.4M | Series B | Jan 14, 2021 |  |
| Dima Biotech | Dima Biotech is a tumor immunotherapy and monoclonal antibody developer, specializing in the development of recombinant monoclonal antibodies for tumor immune products and services. It has the unique RECmAb digital monoclonal antibody technology, which can be used to obtain a variety of genus and high quality. Monoclonal antibodies. |  | Angel | Sep 11, 2019 |  |

10 of 14 investments shown.

## Co-investors
- [Huatai Zijin Investment](https://shizune.co/investors/profile/huatai-zijin-investment) — VC Fund, 3 deals together
- [Bondshine Capital](https://shizune.co/investors/profile/bondshine-capital) — VC Fund, 2 deals together
- [Fang Fund Partners](https://shizune.co/investors/profile/fang-fund-partners) — VC Fund, 2 deals together
- Anji Yunshuo — VC Fund, 1 deal together
- Binghong Capital — VC Fund, 1 deal together
- BridgeOne Capital — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Guoqian Venture Capital invest in?

Guoqian Venture Capital invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Angel stage. Most of the 14 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Guoqian Venture Capital?

Public channels for Guoqian Venture Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Guoqian Venture Capital?

The team at Guoqian Venture Capital includes Chen Hao (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co